Kite Pharma CEO Arie Belldegrun feels his company is inching closer to its goal of being the first to file for FDA approval of an engineered T-cell treatment for cancer. But investors have been asking some tough questions.

from Forbes – Tech http://ift.tt/2dCy1EB
via IFTTT